Saier MH Jr. Families of transmembrane sugar transport proteins. Mol Microbiol 2000;35:699-710.

Wright EM. Glucose transport families SLC5 and SLC50. Mol Asp Med 2013;34:183-96.

Mueckler M, Thorens B. The SLC2 (GLUT) family of membrane transporters. Mol Asp Med 2013;34:121-38.

Szablewski L. Expression of glucose transporters in health. In: Human glucose transporters in health and diseases, L. Szablewski (Ed.), Cambridge Scholars Publ. 2019:5-61.

Uldry M, Ibberson M, Horisberger J-D, et al. Identification of a mammalian H+-myo-inositol symporter expressed predominantly in the brain. EMBO 2001;20:4467-77.

Deng D, Yan N. GLUT, SGLT, and SWEET: structure and mechanistic investigations of the glucose transporters. Prot Sci 2016;25:546-58.

Wright EM. Renal Na+/glucose cotransporters. Am J Physiol 2001;280:F10-F8.

Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Pflügers Arch – Eur J Physiol 2004;447:510-8.

Turk E, Wright EM. Membrane topology motifs in the SGLT cotransporter family. J Membr Biol 1997;159:1-20.

Bianchi L, Diez-Sampedro A. A single amino acid change converts the sugar sensor SGLT3 into a sugar transporter. PLoS ONE 2010;5:e10241.

Warburg O. The chemical constitution of respiratory ferment. Science. 1928:68;437-443.

Warburg, O. On the origin of cancer cells. Science 1956;123:309-14.

Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell 2017;168:657-69.

Fan C, Tang Y, Xiong F, et al. Role of long non-coding RNAs in glucose metabolism in cancer. Mol Canc 2017;16:130.

Cairns RA, Kalliomaki T, Hill RP. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Canc Res 2001;61:8903-8.

Barron CC, Bilan PJ, Tsakiridis T, Tsiani E. Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism 2016;65:124-39.

Szablewski L. Expression of glucose transporters in cancers. Biochim Biophys Acta Rev Canc 2013;1835:164-9.

Nowak N, Kulma A, Gutowicz J. Up-regulation of key glycolysis proteins in cancer development. Open Life Sci 2018;13:569-81.

Zhao ZX, Lu LW, Qiu J, et al. Glucose transporter-1 as an independent prognostic marker for cancer: A meta-analysis. Oncotarget 2018;9:2728-38.

Pliszka M, Szablewski L. Glucose transporters as a target for anticancer therapy. Cancers 2021;13:4184.

Airley RE, Mobasheri A. Hypoxic regulation of glucose transport anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 2007;53:233-56.

Mano Y, Aishima S, Kubo Y, et al. Correlation between biological marker expression and fluorine-18 fluorodeoxyglucose uptake in hepatocellular carcinoma. Am J Clin Pathol 2014;142:391-7.

Mohd Abdul Rashid MB, Toh TB, Silva A, et al. Identification and optimization of combinatorial glucose metabolism inhibitors in hepatocellular carcinomas. J Lab Autom 2015;20:423-37.

Amann T, Maegdefrau U, Hartmann A, et al. GLUT1 expression is increased in hepatocellularly carcinoma and promotes tumorigenesis. Am J Pathol 2009;174:1544-52.

Daskalow K, Pfander D, Weichert W, et al. Distinct temporospatial expression patterns of glycolysis-related proteins in human hepatocellular carcinoma. Histochem Cell Biol 2009;132:21-31.

Roh MS, Jeong JS, Kim YH, et al. Diagnostic utility of GLUT1 in the differential diagnosis of liver carcinoma. Hepatogastroenterology 2004;51:1315-8.

Kurata T, Oguri T, Isobe T, et al. Differential expression of facilitative glucose transporter (GLUT) genes in primary lung cancers and their liver metastases. Jpn J Canc Res 1999;90:1238-43.

Carvalho KC, Cunha IW, Roch RM, et al. GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics 2011;66:965-72.

Paudyal B, Paudyal P, Oriuchi N, et al. Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma. Int J Oncol 2008;33:1047-54.

Grobholz R, Hacker HJ, Thorens B, Bannasch P. Reduction in the expression of glucose transporter protein GLUT2 in preneoplastic and neoplastic hepatic lesions and reexpression of GLUT1 in late stages of hepatocarcinogenesis. Canc Res 1993;53:4204-11.

Ebert BL, Gleadle JM, O’Rourke JF, et al. Isoenzyme-specific regulation of genes involved in energy metabolism by hypoxia: similarity with the regulation of erythropoietin. Biochem J 1996;313:809-14.

Godoy A, Ulloa V, Rodŕiquez F, et al. Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol 2006;207:614-27.

Kayano T, Burant CF, Fukumoto H, et al. Human facilitative glucose transporters. Isolation, functional characterization, and gene localization of cDNA encoding an isoform (GLUT5) expressed in small intestine, kidney, muscle, and adipose tissue an unusual glucose transporter pseudogene-like sequence (GLUT6). J Biol Chem 1990;265:13276-82.

Lei S, Yang J, Chen C, et al. FLIPL is critical for aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Canc Res 2016;35:79.

Kim, Y.W.; Park, Y.K.; Yoon, T.; Lee, S.M. Expression of GLUT-1 glucose transporter in gallbladder carcinoma. Hepato-Gastroenterology 2002;49:907-11.

Legan M, Tevzić S, Tolar A, et al. Glucose transporter-1 (GLUT-1) immunoreactivity in benign, premalignant and malignant lesions of the gallbladder. Pathol Oncol Res 2011;17:61-66.

Paudyal B, Oriuchi N, Paudyal P, et al. Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2fluoro-2-deoxy-D-glucose positron emission tomography. Canc Sci 2008;99:260-6.

Kubo Y, Aishima S, Tanaka Y, et al. Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma. Hum Pathol 2014;45:1610-7.

Basturk IO, Singh R, Kaygusuz E, et al. GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis. Pancreas 2011;40:187-92.

Sampedro-Núñez M, Bouthelier A, Serran-Somavilla A, et al. LAT-1 and GLUT-1 carrier expression and its prognostic value in gastroenteropancreatic neuroendocrine tumors. Cancers 2020;12:2968.

Low SK, Giannis D, Bahaie NS, et al. Competing mortality in patients with neuroendocrine tumors. Am J Clin Oncol 2019;42:668-74.

Pavel M, Oberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annu Oncol 2020;31:844-60.

Chai SM, Brown IS, Kumarasinghe MP. Gastroenteropancreatic neuroendocrine neoplasms: Selected pathology review and molecular updates. Histopathology 2018;72:153-67.

Binderup T, Knigge UP, Federspiel B, et al. Gene expression of glucose transporter 1 (GLUT1), hexokinase 1 and hexokinase 2 in gastroentero-pancreatic neuroendocrine tumors: correlation with F-18-fluoro-deoxy-glucose positron emission tomography and cellular proliferation. Diagnostic 2013;3:372-84.

Panzuto F, Baoninsegna L, Fazio N, et al. Metastatic and locally advances pancreatic endocrine carcinomas: Analysis of factors associated with disease progression. J Clin Oncol 2011;29:2372-7.

Lu K, Yang J, Li D-C, et al. Expression of clinical significance of glucose transporter-1 in pancreatic cancer. Oncol Lett 2016;12:243-9.

Chaika N, Yu F, Purohit V, et al. Differential expression of metabolic genes in tumor and stromal components of primary and metastatic loci in pancreatic adenocarcinoma. PLOS ONE 2012;7:e32996.

Yang H-J, Xu W-J, Guan Y-H, et al. Expression of Glut-1 and HK-II in pancreatic cancer and their impact on prognosis and FDFG accumulation. Transl Oncol 2016;9:583-91.

Chikamoto A, Inoue R, Komohara Y, et al.; Preoperative high maximum standardized uptake value in association with glucose transporter 1 predicts poor prognosis in pancreatic cancer. Ann Surg Oncol 2017;24:2040-60.

Boira MA, Di Martino M, Gordillo C, et al. GLUT-1 as a predictor of worse prognosis in pancreatic adenocarcinoma: immunohistochemistry study showing the correlation between expression and survival. BMC Cancer 2020;20:909.

Chen X, Lu P, Zhou S, et al. Predicted value of glucose transporter-1 and glucose transporter-3 for survival of cancer patients: A meta-analysis. Oncotarget 2017;8:13206-13.

Yu M, Yongzhi H, Chen S, et al. The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis. Oncotarget 2017;8:43356-67.

Pizzi S, Porzionato A, Pasquali C, et al. Glucose transporter-1 expression and prognostic significance in pancreatic carcinogenesis. Histol Histopathol 2009;24:175-85.

Kurahara H, Maemura K, Mataki, Y, et al. Significance of glucose transporter type 1 (GLUT-1) expression in the therapeutic strategy for pancreatic ductal adenocarcinoma. Ann Surg Oncol 2018;25:1432-9.

Fujino M, Aishima S, Shindo K, et al. Expression of glucose transporter-1 is correlated with hypoxia-inducible factor 1α and malignant potential in pancreatic neuroendocrine tumors. Oncol Lett 2016;12:3337-43.

Ito H, Duxbury M, Zinner MJ, et al. Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. Surgery 2004;136:548-56.

Higashi T, Tamaki N, Honda T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 1997;38:1337-44.

Fendrich V, Schneider R, Maitra A, et al. Detection of precursor lesions of pancreatic adenocarcinoma in PET-CT in a genetically engineered mouse model of pancreatic cancer. Neoplasia 2011;13:180-6.

Seino Y, Yamamoto T, Inoue K, et al. Abnormal facilitative glucose transporter gene expression in human islet cell tumors. J Clin Endocrinol Metab 1993;76:75-8.

Reske SN, Grillenberger KG, Glatting G, et al. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 1997;38:1344-8.

Liu J, Knezetic A, Strömmer L, et al. The intracellular mechanism of insulin resistance in pancreatic cancer patients. J Clin Endocrinol Metab 2000:85;1232-1238.

Scafoglio C, Hiaryama BA, Kepe V, et al. Functional expression of sodium-glucose transporters in cancer. PNAS 2015;112:E4111-E9.

Calco MB, Figurea A, Pulido EG, et al. Potential role of sugar transporters and their relationship with anticancer therapy. Int J Endocrinol 2010;205357.

Casneuf VF, Fonteyne P, Van Damme N, et al. Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. Canc Invest 2008;26:852-9.

Kim WS, Kim YY, Jang SJ, Jung MH. Glucose transporter 1 (GLUT1) expression is associated with intestinal type of gastric carcinoma. J Korean Med Sci 2000;15:420-4.

Kawamura T, Kusakabe T, Sugino T. Expression of glucose transporter-1 in human gastric carcinoma. Cancer 2001;92:634-41.

Zhou D, Jiang L, Jin L, et al. Glucose transporter-1 cooperating with AKT signaling promote gastric cancer progression. Canc Manag Res 2020;12:4151-60.

Noguchi Y, Marat D, Saito A, et al. Expression of facilitative glucose transporters in gastric tumors. Hepatogastroenterology 1999;46:2683-9.

Medina RA, Owen GI. Glucose transporters: expression, regulation and cancer. Biol Res 2002;72:113-7.

Noguchi Y, Okamoto T, Marat D, et al. Expression of facilitative glucose transporter 1 mRNA in colon cancer was not regulated by k-ras. Canc Lett 2000;154:137-42.

Cooper R, Sarioğlu S, Sökmen S, et al. Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma. Br J Canc 2003;89:870-6.

Saigusa S, Toiyama Y, Tanaka K, et al. Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy. Surg Today 2012;42:460-9.

Airley R, Evans A, Mobasheri A, Hewit SM. Glucose transporter Glut-1 is detectable in peri-necrotic regions in many tumor types but not normal tissues: Study using tissue microarrays. Ann Anat 2010;192:133-8.

Furudoi A, Tanaka S, Haruma K, et al. Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 2001;60:162-9.

Winiewicz A, Sulkowska M, Koda M, et al. Significant expression of GLUT-1, Bcl-XL, and Bax in colorectal cancer. Ann NY Acad Sci 2007;1095:53-61.

Haber RS, Rathan A, Weiser KR, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 1998;83:34-40.

De Wit M, Jimenez CR, Carvalho B, et al. Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression. Gut 2012;61:855-64.

Douard V, Ferraris RP. Regulation of the fructose transporter GLUT5 in health and disease. Am J Physiol Endocrinol 2008;295:E227-E37.

Bissonnette P, Gagné H, Coady MJ, et al. Kinetic separation and characterization of three sugar transport models in CaCo-2 cells. Am J Physiol 1996;270:G833-G43.

Guo GF, Cai YC, Zhang B, et al. Overexpressing of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis. Med Oncol 2011;28:S197-S203.

Gnjidić M, Fucak IK. Renal cell carcinoma: molecular pathways and targeted therapy. Period Biol 2014;116:393-8.

Sringley JR, Delahunt B, Eble JN. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Ann J Surg Pathol 2013;37:1469-89.

Linehan WM. Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics. Gen Res 2012;22:2089-100.

Inamura K. Translational renal cell carcinoma: an update on clinicopathological and molecular features. Cancer 2017;9:111.

Szablewski L. Distribution of glucose transporters in renal diseases. J Biomed Sci 2017;24:64.

Szablewski L. Expression of glucose transporters in diseases. In: Human glucose transporters in health and diseases. L. Szablewski (Ed.), Cambridge Scholars Publ 2019;63-227.

Page T, Hodgkinson AD, Ollerenshow M, et al. Glucose transporter polymorphisms are associated with clear-cell renal carcinoma. Canc Genet Cytogenet 2005;163:151-5.

Ozcan A, Shen SS, Zhai QJ, Truong LD. Expression of GLUT in primary renal tumors. Morphologic and biologic implications. Am J Clin Pathol 2007;128:245-54.

Soltysova A, Breza J, Takacova M, et al. Deregulation of energetic metabolism in the clear cell renal cell carcinoma: A multiple pathway profiling. Int J Oncol 2015;47:287-95.

Singer K, Kastenberger M, Gottfried E, et al. Warburg phenotype in renal cell carcinoma: a high expression of glucose transporter-1 (GLUT-1) correlates with low CD8+ T-cell infiltration in the tumor. Int J Canc 2011;128:2085-95.

Aparicio LMA, Villaamil VM, Calvo MB, et al. Glucose transporter expression and the potential role of fructose in renal cell carcinoma: A correlation with pathological parameters. Mol Med Rep 2010;3:575-80.

Chan DA, Sutphin PD, Nguyen P, et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med 2011;3:94ra70.

Suganuma N, Segade F, Matsuzu K, Bowden DW. Differential expression of facilitative glucose transporters in normal and tumour kidney tissues. BJU Inter 2007;99:1143-9.

Massari F, Ciccarese C, Santoni M, et al. Metabolic phenotype of bladder cancer. Canc Treat Rev 2016;45:46-57.

Lee J-H, Kim Y-W, Chang S-G. Glucose transporter-1 expression in urothelial papilloma of the bladder. Urol Int 2005;74:268-71.

Chang S, Lee S, Lee C, et al. Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. Urology 2000;55:448-52.

Reis H, Tschirdewahn S, Szarvas T, et al. Expression of GLUT1 is associated with increasing grade of malignancy in non-invasive and invasive urothelial carcinomas of the bladder. Oncol Lett 2011;2:1149-53.

Wang J, Ye C, Chen C, et al. Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis. Oncotarget 2017;8:16886.

Zhao Z-X, Lu L-W, Qiu J, et al.Glucose transporter-1 as an independent prognostic marker for cancer: a meta-analysis. Oncotarget 2018;9:2728-38.

Boyaci C, Behzatoglu K. Diagnostic value of glucose transporter 1 (glut-1) expression in nested variant of urothelial carcinoma. Turk J Pathol 2018;1:2-7.

Ou Y-C, Tsai Y-S, Liv C-J, et al. Glucose transporter-3 expression predicts poor prognosis in human bladder urothelial carcinoma and is associated with epithelial mesenchymal transition. Eur Urol Suppl 2015;14/2:e233.

Mc Neal JE. Normal histology of the prostate. Am J Surg Pathol 1998;12:619-33.

Gonzalez-Menendez P, Hevia D, Mayo JC, Sainz RM. The dark side of glucose transporters in prostate cancer: Are they a new future to characterize carcinomas? Int J Canc 2018;42:2414-24.

Reinicke K, Sotomayor P, Cisterna P, et al. Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue. J Biol Biochem 2012;113:553-62.

Gasinska A, Jaszczyński J, Rychlik U, et al. Prognostic significance of serum PSA level and telomerase, VEGF and GLUT-1 protein expression for the biochemical recurrence in prostate cancer patients after radical prostatectomy. Pathol Oncol 2020;26:1049-56.

Effert P, Beniers AJ, Tamimi Y, et al. Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. Anticanc Res 2004;24:3057-64.

Khandani AH, Funkhouser WK, Feins R, Socinski MA. Simultaneous FDG PET+/Glut1+ lung and FDG PET-/Glut1- subcranial lymph node metastases from prostate cancer. Ann Nucl Med 2009;23:595-7.

Gonzalez-Mendez P, Hevia D, Rodriquez-Garcia A, et al. Regulation of GLUT transporters by flavonoids in androgen-sensitive and –insensitive prostate cancer cells. Endocrinology 2014;155:3238-50.

Sangkop F, Singh G, Rodrigues E, et al. Changes in cellular uric acid homeostasis facilitated by Glucose Transporter (GLUT9) drive activing sensitivity and prostate cancer behavior. Physiol Proc Physiol Soc 2016;37:PCB129.

Chandler JD, Williams ED, Slavin JL, et al. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer 2003;97:2035-42.

Blessing A, Xu L, Gao G, et al. Sodium/glucose co-transporter 1 expression increases in human diseased prostate. J Canc Sci Ther 2012;4:306-12.

Mendez LE, Manci N, Cantuaria G, et al. Expression of glucose transporter-1 in cervical cancer and its precursors. Gynecol Oncol 2002;86:138-43.

Huang X-O, Chen X, Xie X-X, et al. Co-expression of CD147 and GLUT-1 induces radiation resistance and poor prognosis in cervical squamous cell carcinoma. Int J Clin Exp Pathol 2014;7:1651-66.

Airlay R, Lancaster J, Davidson S, et al. Glucose transporter Glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Canc Res 2001;7:928-34.

Wang BY, Kalir T, Sabo E, et al. Immunohistochemical staining of GLUT-1 in benign, hyperplastic and malignant endometrial epithelia. Cancer 2000;88:2774-81.

Khabaz MN, Qureshi IA, Al-Magrabi JA. GLUT1 expression is a supportive mean in predicting prognosis and survival estimates of endometrial carcinoma. Ginekol Pol 2019;90:582-8.

Andrade J, Choi Y, Baker W, et al. Estrogens rapidly stimulate expression of GLUT6, a glucose transporter overexpressed in obesity-linked endometrial cancer. Endocrine Societ’s 97th Ann Meet Expo San Diego. 2015;SAT-322.

Cantuaria G, Magalhaes A, Penalver M, et al. Expression of GLUT-1 glucose transporter in borderline and malignant tumors of the ovary. Gynecol Oncol 2000;79:33-7.

Cantuaria G, Fagotti A, Ferrandina G, et al. GLUT-1 expression in ovarian carcinoma. Association with survival and response to chemotherapy. Cancer 2001;92:1144-50.

Cai Y, Zhai J, Feng B, et al. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor. J Obstet Gynecol Res 2014;40:1925-30.

Kalir T, Wang BY, Goldfischer M, et al. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia. Cancer 2002;94:1078-82.

Kalir T, Rahaman J, Hagopian G, et al. Immunohistochemical detection of glucose transporter in benign and malignant fallopian tube epithelia, with comparison to ovarian carcinomas. Arch Pathol Lab Med 2005;129:651-4.

Semaan A, Munkarah AR, Arabi H, et al. Expression of GLUT1 in epithelial ovarian carcinoma: Correlation with tumor proliferation, angiogenesis, survival and ability to predict optimal cytoreduction. Gynecol Oncol 2011;121:181-6.

Cho H, Lee YS, Kim J, et al. Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer. Canc Invest 2013;31:607-15.

Shin SJ, Kim JY, Kwon SY, et al. Ciglitazone enhances ovarian cancer cell death via inhibition of glucose transporter-1. Eur J Pharmacol 2014;743:17-23.

Rudlowski C, Moser M, Becker AJ, et al. GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer. Oncology 2004;66:404-10.

Kellenberger LD, Bruin JE, Greenway J, et al. The role of dysregulated glucose metabolism in epithelial ovarian cancer. J Oncol 2010;514310.

Lai B, Xiao Y, Pu H, et al. Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinoma. Arch Gynecol Obstet 2012;285:1455-61.

Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-94.

Brown RS, Leung JY, Kison PV, et al. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999;40:556-65.

Choi WH, Yoo IR, O JH, et al. Is the Glut expression related to FDG uptake in PET/CT of non-small cell lung cancer patients? Technol Health Care 2015;23:S311-S8.

Na KJ, Choi H, Oh HR, et al. Reciprocal change in glucose metabolism of cancer and immune cells mediated by different glucose transporters predicts immunotherapy response. Theranostatics 2020;10:9579-90.

Minami JI, Saito Y, Immamura H, Okamura A. Prognostic significance of p53 VEGF and Glut-1 in resected stage 1 adenocarcinoma of the lung. Lung Canc 2002;38:51-7.

Zhang B, Xie Z, Li B. The clinicopathological impacts and prognostic significance of GLUT1 expression in patients with lung cancer: A meta-analysis. Gene 2019;689:76-83.

Sasaki H, Shitara M, Yokota K, et al. Overexpression of GLUT1 correlates with Kras mutations in lung carcinomas. Mol Med Rep 2012;5:559-62.

Osugi J, Yamaura T, Muto S, et al. Prognostic impact of the combination of glucose transporter 1 and ATP citrate lyase in node-negative patients with non-small lung cancer. Lung Canc 2015;88:310-8.

Nguyen XC, Lee WW, Chung J-H, et al. FDG uptake, glucose transporter type 1, and Ki-67 expression in non-small-cell lung cancer: Correlations and prognostic values. Eur J Radiol 2007;62:214-9.

Chuang J-H, Lee WW, Park SY, et al. FDG uptake and glucose transporter type 1 expression in lymph nodes of non-small cell lung cancer. EJSO 2006;32:989-95.

Zhao H, Sun J, Shao J, et al. Glucose transporter 1 promotes the malignant phenotype of non-small cell lung cancer through integrin β1/Src/FAK signaling. J Canc 2019;10:4989-97.

Tan Z, Yang C, Zhang X, et al. Expression of glucose transporter 1 and prognostic in non-small cell lung cancer: a pooled analysis of 1665 patients. Oncotarget 2017;8:60954-61.

Masin M, Vazquez J, Rossi S, et al. GLUT3 is induced during epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung cancer. Canc Metab 2014;2:11.

Tuccinardi T, Granchi C, Iegre J, et al. Oxime-based inhibitors of glucose transporter 1 (GLUT1) displaying antiproliferative effects in cancer cells. Bioorg Med Chem Let 2013;23:6923-7.

Granchi C, Qian Y, Lee HY, et al. Salicyloketoximes targeting glucose transporter 1 restrict energy supply to lung cancer cells. Chem Med Chem 2015;10:1892-900.

Ito T, Noguchi Y, Udaka N, et al. Glucose transporter expression in developing fetal lungs and lung neoplasma. Histol Histopathol 1999;14:895-904.

Ito T, Noguchi Y, Satoh S, et al. Expression of facilitative glucose transporters isoforms in lung carcinomas: its relation to histologic type, differentiation grade and tumor stage. Mod Pathol 1998;11:437-443.

Barron C, Tsiani E, Tsakiridis T. Expression of glucose transporters GLUT1, GLUT3, GLUT4, and GLUT12 in human cancer cells. BMC Proc 2012;6:Suppl.3,P4.

Ozbudak IH, Shilo K, Tavora F, et al. Glucose transporter-1 in pulmonary neuroendocrine carcinomas: expression and survival analysis. Mod Pathol 2009;22:633-8.

Song YS, Lee WW, Chung J-H, et al. Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. Lung Canc 2008;61:54-60.

Lee J, Kim JO, Jung CK, et al. Metabolic activity on [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography and glucose transporter-1 expression might predict clinical outcomes in patients with limited disease small-cell lung cancer who receive concurrent chemoradiation. Clin Lung Canc 2014;15:e13-21.

Pedersen MWB, Holm S, Lund EL, et al. Correlation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-lung cancer (SCLC) sublines in vivo and in vitro. Neoplasia 2001;3:80-7.

Zhao P, Wang W, Yang L, Gaole A. The expression and regulation of glucose transporters in tumor cells. Adv Med Oncol Res 2016;2:6.

Ishikawa N, Oguri T, Isobe T, et al. SGLT gene expression in primary lung cancers and their metastatic lesions. Jap J Canc Res 2001;92:874-9.

Scafoglio CR, Villegas B, Abdelhady G, et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci Transl Med 2018;10:eaat5933.

Wapnir IL, Van de Rijn M, Nowels K, et al. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab 2003;88:1880-8.

Mo L, Chen Q, Yang Y, et al. High expression of GLUT1 and GLUT3 correlate with neoadjuvant chemotherapy infectiveness breast cancer patients. Int J Clin Path 2016;9:9555-6.

Zheng C, Yang K, Zhang M, et al. Specific protein 1 depletion attenuates glucose uptake and proliferation of human glioma cells by regulating GLUT3 expression. Oncol Lett 2016;12:125-31.

Coelho RG, Fortunato RS, Carvalho DP. Metabolic reprogramming in thyroid carcinoma. Front Oncol 2018;8:82.

Chai YJ, Wook J, Oh SW, et al. Upregulation of SLC2 (GLUT) family genes is related to poor survival outcomes in papillary thyroid carcinoma: Analysis of data from The Center Genome Atlas. Surgery 2017;161:188-94.

Fan J, Mei J, Zhang M-Z, et al. Clinicopathological significance of glucose transporter protein-1 overexpression in human osteosarcoma. Oncol Lett 2017;14:2439-45.

Bandyopadhyay A, Panda A, Behura A, et al. Glucose transporter 1 expression in odontogenic keratynocyst, dentigerous cyst, and ameloblastoma. An immunohistochemical study. J Contemp Dent Pract 2017;18:366-70.

Liu T, Kishton RJ, Macintyre AN, et al. Glucose transporter 1-mediated glucose uptake is limiting for B-cell acute lymphoblastic leukemia anabolic metabolism and resistance to apoptosis. Cell Death Dis 2014;5:e1516.